Back to Search
Start Over
Preclinical Evaluation of interferon-gamma primed human Wharton's jelly-derived mesenchymal stem cells.
- Source :
-
Human & Experimental Toxicology . Jan-Dec2023, Vol. 42, p1-11. 11p. - Publication Year :
- 2023
-
Abstract
- The potential of human mesenchymal stem cells (MSCs) for cell therapy has been investigated in numerous immune-mediated conditions; MSCs are considered one of the most promising cellular therapeutics to treat intractable diseases. Recently, approaches to prime MSCs have been investigated, thereby generating cellular products with enhanced potential for a variety of clinical applications. Interferon-gamma (IFN-γ) priming is a current approach used to increase the therapeutic efficacy of MSCs. In this study, we determined the systemic toxicity, tumorigenicity and biodistribution of IFN-γ-primed Wharton's jelly-derived (WJ)-MSCs in male and female BALB/c-nu/nu mice. There were no deaths or pathologic lesions in the mice treated with 5 × 106 cells/kg IFN-γ-primed MSCs in the repeated dose study. In the tumorigenicity study, one of the subcutaneously treated mice showed bronchioloalveolar adenoma in the lung but tested negative for human-specific anti-mitochondrial antibody, suggesting the spontaneous murine origin of the adenoma. A biodistribution study using real-time quantitative polymerase chain reaction demonstrated the systemic IFN-γ-primed MSC clearance by day 28. Based on the toxicity, biodistribution, and tumorigenicity studies, we concluded that IFN-γ-primed MSCs at 5 × 106 cells/kg do not induce tumor formation and adverse changes. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09603271
- Volume :
- 42
- Database :
- Academic Search Index
- Journal :
- Human & Experimental Toxicology
- Publication Type :
- Academic Journal
- Accession number :
- 175197559
- Full Text :
- https://doi.org/10.1177/09603271231171650